Literature DB >> 7835271

Action of metformin on glucose transport and glucose transporter GLUT1 and GLUT4 in heart muscle cells from healthy and diabetic rats.

Y Fischer1, J Thomas, P Rösen, H Kammermeier.   

Abstract

The effects of the antidiabetic drug metformin on glucose transport were investigated in freshly isolated heart muscle cells from healthy and streptozotocin-diabetic rats. In vivo treatment of diabetic rats with metformin failed to affect the basal and insulin-stimulated rate of glucose transport measured in isolated cells. In vitro exposure to therapeutic concentrations (< or = 10(-4) M) of metformin did not influence glucose transport, even upon incubation times up to 5 h or in the presence of high glucose (20 nM). In contrast, higher metformin concentrations produced an 8- to 12-fold increase in glucose uptake (with a lag of 90 min, and a maximum at 180 min and approximately 5 mM). In the presence of submaximal insulin concentrations (< or = 3.10(-10) M), the effects of metformin (5 mM) and of insulin were more than additive, whereas, at saturating insulin concentrations (10(-8) M), partial additivity was observed. Like insulin, metformin caused an approximately 1.6-fold increase in the content of both glucose transporter isoforms GLUT1 and GLUT4 in the plasma membrane of cardiac myocytes, with a corresponding decrease in an intracellular membrane fraction. cAMP-elevating treatments depressed the metformin-, but not the insulin-dependent glucose uptake, by 20-30%. In myocytes from diabetic rats, the rate of metformin-activated glucose transport was similar to that of cells from control animals, whereas basal and insulin-stimulated transport were substantially diminished. Finally, metformin (5 mM) induced a slight depression of oxygen consumption and energy metabolism of myocytes (as determined by measuring their level of energy-rich phosphates) comparable to the effects of hypoxia in rat hearts. In conclusion, these data do not provide evidence in favor of the hypothesis that glucose uptake by muscle tissue represents the site of metformin's therapeutic action in vivo. On the other hand, the large, insulin-independent effect of metformin at high concentrations (approximately mM) in vitro may be related to the action of hypoxia and occurs through a redistribution of glucose carriers from an intracellular locus to the plasma membrane. The mechanism (or signal) involved in metformin's action is likely to differ from that triggered by insulin and is not impaired in the diabetic state.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7835271     DOI: 10.1210/endo.136.2.7835271

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  23 in total

1.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.

Authors:  M R Owen; E Doran; A P Halestrap
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

2.  Chromium picolinate positively influences the glucose transporter system via affecting cholesterol homeostasis in adipocytes cultured under hyperglycemic diabetic conditions.

Authors:  Guruprasad R Pattar; Lixuan Tackett; Ping Liu; Jeffrey S Elmendorf
Journal:  Mutat Res       Date:  2006-07-25       Impact factor: 2.433

3.  Glucose transport and glucose transporter GLUT4 are regulated by product(s) of intermediary metabolism in cardiomyocytes.

Authors:  Y Fischer; U Böttcher; M Eblenkamp; J Thomas; E Jüngling; P Rösen; H Kammermeier
Journal:  Biochem J       Date:  1997-02-01       Impact factor: 3.857

4.  Heterologous expression of rab4 reduces glucose transport and GLUT4 abundance at the cell surface in oocytes.

Authors:  S Mora; I Monden; A Zorzano; K Keller
Journal:  Biochem J       Date:  1997-06-01       Impact factor: 3.857

5.  Regulation by metformin of the hexose transport system in vascular endothelial and smooth muscle cells.

Authors:  S Sasson; N Gorowits; H G Joost; G L King; E Cerasi; N Kaiser
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

6.  Metformin Promotes 2-Deoxy-2-[18F]Fluoro-D-Glucose Uptake in Hepatocellular Carcinoma Cells Through FoxO1-Mediated Downregulation of Glucose-6-Phosphatase.

Authors:  Zhengjie Wang; Fei Kang; Yongheng Gao; Yi Liu; Xiaolong Xu; Xiaowei Ma; Wenhui Ma; Weidong Yang; Jing Wang
Journal:  Mol Imaging Biol       Date:  2018-06       Impact factor: 3.488

Review 7.  Metformin--mode of action and clinical implications for diabetes and cancer.

Authors:  Ida Pernicova; Márta Korbonits
Journal:  Nat Rev Endocrinol       Date:  2014-01-07       Impact factor: 43.330

8.  Antidiabetogenic effects of chromium mitigate hyperinsulinemia-induced cellular insulin resistance via correction of plasma membrane cholesterol imbalance.

Authors:  Emily M Horvath; Lixuan Tackett; Alicia M McCarthy; Priya Raman; Joseph T Brozinick; Jeffrey S Elmendorf
Journal:  Mol Endocrinol       Date:  2007-12-28

Review 9.  Therapeutic Concentrations of Metformin: A Systematic Review.

Authors:  Farshad Kajbaf; Marc E De Broe; Jean-Daniel Lalau
Journal:  Clin Pharmacokinet       Date:  2016-04       Impact factor: 6.447

10.  Effects of cAMP modulators on long-chain fatty-acid uptake and utilization by electrically stimulated rat cardiac myocytes.

Authors:  J J F P Luiken; J Willems; S L M Coort; W A Coumans; A Bonen; G J Van Der Vusse; J F C Glatz
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.